Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer-Reference-Cited by-同舟云学术

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Published:2020-12-24 Issue:26 Volume:383 Page:2586-2588
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Aydillo Teresa,Gonzalez-Reiche Ana S.,Aslam Sadaf,van de Guchte Adriana,Khan Zenab,Obla Ajay,Dutta Jayeeta,van Bakel Harm,Aberg Judith,García-Sastre Adolfo,Shah Gunjan,Hohl Tobias,Papanicolaou Genovefa,Perales Miguel-Angel,Sepkowitz Kent,Babady N. Esther,Kamboj Mini

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

JPB Foundation

Center for Scientific Review

Robin Chemers Neustein Postdoctoral Fellowship Award.

NIH/NCI

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2031670

Cited by 363 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study;Virology Journal;2024-09-09

2. A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy;BMC Infectious Diseases;2024-09-02

3. Infectious Disease Prophylaxis During and After Immunosuppressive Therapy;Kidney International Reports;2024-08

4. Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications;BMC Infectious Diseases;2024-07-25

5. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection;Journal of Infection and Chemotherapy;2024-07